Lounes Djerroudi, Ahmad El Sabeh-Ayoun, Camille Benoist, Gaelle Pierron, Julien Masliah-Planchon, Laetitia Fuhrmann, Yann Kieffer, Matthieu Carton, Toulsie Ramtohul, Celine Callens, Victor Renault, François-Clément Bidard, Fatima Mechta-Grigoriou, Anne Vincent-Salomon
Invasive lobular carcinomas (ILCs) have a low frequency of ERBB2 amplification, therefore restricting the use of conventional anti-HER2 therapies for this histological special type. Conversely, ILCs with low HER2 overexpression may represent a broader target for the use of emerging anti-body drug conjugate therapies targeting HER2, since these treatments have proven effective in HER2-low breast cancers. Very scarce data about HER2-low ILCs have been so far published, although these tumors could have different prevalence and histo-molecular specificities compared to invasive breast carcinoma of no special type (IBC-NST)...
February 28, 2024: Modern Pathology